Nature published a long-read on June 8 reviewing the consumer peptide boom against the actual evidence base. Worldwide Google searches for 'peptides' rose from about 1.3 million per month in 2024 to around 8 million in 2026, fueled by social media. Most popularly promoted compounds (BPC-157, TB-500, GHK-Cu, CJC-1295) rest on animal data, with one human study described as showing 'significant methodological problems and no control group.' The piece lands two months before the July 23-24 PCAC meeting that will rule on whether seven of these peptides can return to legal 503A compounding.
A Nature paper published May 6 from a University of Virginia team developed humanized GLP1R mouse models to investigate how small-molecule GLP1R agonists — including orforglipron (Foundayo) — regulate feeding behavior. Beyond canonical hypothalamic and hindbrain networks that control metabolic homeostasis, the team showed these oral compounds recruit a discrete population of Glp1r-expressing neurons in the central amygdala and selectively suppress consumption of palatable foods by reducing dopamine release in the nucleus accumbens — a parallel hedonic-feeding circuit distinct from the homeostatic mechanism that drives most GLP-1 weight loss. The work explains why patients on small-molecule oral GLP-1s often report reduced food cravings and pleasure-driven eating, and identifies a neural circuit with implications for substance-use disorder and binge eating beyond obesity.
The international TransCODE Consortium published a Nature paper May 6 reporting that roughly 25% of 7,264 non-canonical open reading frames (ncORFs) give rise to detectable peptides, based on a meta-analysis of 95,520 proteomics experiments. The work identifies 1,785 previously unrecognized microproteins, expands the human proteome by ~10%, and introduces the conceptual model of 'peptideins' — microproteins with indeterminate functional potential. Most peptideins are under 50 amino acids and lack similarity to traditional proteins. The consortium, launched in 2022, includes GENCODE, PeptideAtlas, HUPO-HPP, and HUPO-HIPP and aims to set the reference annotation standard for ncORF-encoded microproteins.
A study published in Nature Microbiology used a generative AI approach to discover antimicrobial peptides effective against multidrug-resistant bacteria. The deep learning pipeline screened millions of candidate sequences, achieving a 94.4% success rate in lab validation, with two candidates showing exceptional efficacy and low resistance potential.